| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 2.11 MB | Adobe PDF |
Advisor(s)
Abstract(s)
Introduction - The aim is to evaluate the internal exposure of the family members (FMs) of the patients (PATs) undergoing iodine-131 (131I) thyroid cancer (TC) therapy and quantify the amount of 131I in the FMs, excreted through the urinary. Methods - An observational study with convenience sampling was performed, including 25 PATs and 34 FMs. The PATs, who underwent 131I treatments for TC, were discharged from hospital 48h after therapy. All FMs received instructions on radiation protection, based on Euratom recommendations use and submitted to a questionnaire. A urine sample was collected from every FMs about 70h after discharge of the PAT. Samples of urine were analyzed by gamma spectrometry and counted for 24h. All ethical principles of the investigation were respected. Results - The average activity of 131I given to the PATs (52.9% ♀) was 3266.4 ±1120.2MBq. When the PATs have discharged the average (ᾱ) effective dose rate measured at a 1-metre distance was 7.9±5.8μSv/hr (range 1-25μSv/hr). In the 34 FMs (52.9% ♂) with ᾱ of 48.1±18.6years, only in 3FMs 131I wasn’t detected in the urine. In the other 31 samples urines, the specific activities of 131I have ᾱ of 97.4Bq/L (range 0.0-1146Bq/L). The specific activity of 131I in urine: it is not the same among the classes of the administered activity (p=0.019); don’t is the same on the different classes of FMs ages (p=0.470) and the different degree of relationship (p=0.744). We observed a moderate correlation between the specific activity of 131I in the urine and the activity administered to the PATs (ρsp=0.540; p=0.001) and also between the effective dose rate in the PATs (ρsp=0.730; p<0.001). With a CI of 95%.
Conclusions - The PATs are a radioactive source that can cause exposure of the FMs to ionizing radiation. The specific activity of 131I in the urines of the FMs is related to the activity administered to the PAT. It is clear that FMs of PATs submitted to radioiodine therapy can be subject to internal contamination.
Description
Keywords
Nuclear medicine Iodine-131 Differentiated thyroid carcinoma therapy Family member
Citation
Carapinha MJ, Costa G, Ferreira TC, Salgado L, Carvalho I, Sofia M, et al. Assessment of iodine-131 in the urine of the patient’s family members after differentiated thyroid carcinoma therapy. In: PRS 2017 – Conference "Proteção Radiológica na Saúde 2017", Instituto Superior Técnico (Lisboa), 27-29 de setembro de 2017.